Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.39 |
| ▸ | AKT1 | P31749 | 6/20 | 0.39 |
| ▸ | MTOR | P42345 | 5/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13746484 | 0.93 | PTPN11 (0.41) | PIK3CAAKT1MTORACVR1PKM | |
| SCHEMBL13746452 | 0.84 | ACVR1 (0.42) | ACVR1BRD4ALDH1A1SMN1; SMN2 | |
| SCHEMBL13753991 | 0.84 | ACVR1 (0.40) | PIK3CAAKT1MTORACVR1BRD4 | |
| SCHEMBL8488870 | 0.82 | BRD4 (0.41) | BRD4 | |
| SCHEMBL1487531 | 0.82 | HTR6 (0.38) | BRD4 | |
| SCHEMBL8488593 | 0.82 | HTR6 (0.38) | BRD4 | |
| SCHEMBL3347141 | 0.80 | HTR6 (0.38) | BRD4 | |
| SCHEMBL3354296 | 0.80 | HTR6 (0.43) | BRD4 | |
| SCHEMBL4246057 | 0.80 | ACVR1 (0.48) | PIK3CAAKT1MTORACVR1PKM | |
| SCHEMBL13745685 | 0.79 | PTPN11 (0.42) | BRD4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295433-A2 | JNK inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-20060270646-A1 | Jnk inhibitors | EISAI CO., LTD. (JP) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270646-A1 | Jnk inhibitors | MAPKAPK2, MAPK1, MAPKAPK3 | PIK3CA 1960/4885AKT1 529/4885MTOR 246/4885 |
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | PIK3CA 2108/4885AKT1 561/4885MTOR 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.